148 related articles for article (PubMed ID: 30372367)
21. High-dose Oral Ambroxol for Early Treatment of Pulmonary Acute Respiratory Distress Syndrome: an Exploratory, Randomized, Controlled Pilot Trial.
Baranwal AK; Murthy AS; Singhi SC
J Trop Pediatr; 2015 Oct; 61(5):339-50. PubMed ID: 26130623
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol.
Matthys H; de Mey C; Carls C; Ryś A; Geib A; Wittig T
Arzneimittelforschung; 2000 Aug; 50(8):700-11. PubMed ID: 10994153
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial.
Zhou Y; Sun S; Liu H; Cui L; Chang X; Sun Z
Pharmazie; 2014 Nov; 69(11):842-9. PubMed ID: 25985582
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of an Oral Ambroxol Spray in the Treatment of Acute Uncomplicated Sore Throat.
de Mey C; Patel J; Lakha DR; Richter E; Koelsch S
Drug Res (Stuttg); 2015 Dec; 65(12):658-67. PubMed ID: 25782170
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of lung levels of antibiotics by ambroxol and bromhexine.
Deretic V; Timmins GS
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):213-218. PubMed ID: 30721101
[TBL] [Abstract][Full Text] [Related]
26. [A study of the mechanism of Qingre Huatan therapy in treatment of acute exacerbation of chronic obstructive pulmonary disease by improving airway inflammation and mucus hypersecretion].
Li W; Mao B; Wang G; Wang L; Chang J; Zhang Y; Wan MH; Guo J
Zhong Xi Yi Jie He Xue Bao; 2008 Aug; 6(8):799-805. PubMed ID: 18664347
[TBL] [Abstract][Full Text] [Related]
27. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept.
Schutz A; Gund HJ; Pschorn U; Aicher B; Peil H; Müller A; de Mey C; Gillissen A
Arzneimittelforschung; 2002; 52(3):194-9. PubMed ID: 11963647
[TBL] [Abstract][Full Text] [Related]
28. Effects and mechanisms of ambroxol inhalation (Mucosolvan
Yang Z; Xiao X; Huang Y; He X; Lu Q; Chen S; Lin Z
Pharmazie; 2017 Oct; 72(10):604-607. PubMed ID: 29441886
[TBL] [Abstract][Full Text] [Related]
29. Antiinflammatory properties of ambroxol.
Beeh KM; Beier J; Esperester A; Paul LD
Eur J Med Res; 2008 Dec; 13(12):557-62. PubMed ID: 19073395
[TBL] [Abstract][Full Text] [Related]
30. Biofilm-dependent airway infections: a role for ambroxol?
Cataldi M; Sblendorio V; Leo A; Piazza O
Pulm Pharmacol Ther; 2014 Aug; 28(2):98-108. PubMed ID: 24252805
[TBL] [Abstract][Full Text] [Related]
31. [Ambroxol. Prophylaxis and therapy of pulmonary complications. Symposium on the occasion of the 12th International Sylt Week on Anesthesiology. 9 September 1998].
Anaesthesist; 1998 Nov; 47(11 Suppl Prophylaxe):1-12. PubMed ID: 9884733
[No Abstract] [Full Text] [Related]
32. Oral sustained delivery of ambroxol from in situ-gelling pectin formulations.
Kubo W; Miyazaki S; Dairaku M; Togashi M; Mikami R; Attwood D
Int J Pharm; 2004 Mar; 271(1-2):233-40. PubMed ID: 15129990
[TBL] [Abstract][Full Text] [Related]
33. Ambroxol, bromhexine: anaphylactic reactions.
Prescrire Int; 2015 Apr; 24(159):98. PubMed ID: 25941704
[No Abstract] [Full Text] [Related]
34. Uric acid plasma level and urine pH in rats treated with ambroxol.
Drewa T; Wolski Z; Gruszka M; Misterek B; Lysik J
Acta Pol Pharm; 2007; 64(6):565-7. PubMed ID: 18323253
[TBL] [Abstract][Full Text] [Related]
35. The therapeutic efficacy of high-dose ambroxol and the nursing effects in the treatment of severe pneumonia.
Wang D; Sun S; Hu S
Pak J Pharm Sci; 2019 May; 32(3 Special):1409-1413. PubMed ID: 31551222
[TBL] [Abstract][Full Text] [Related]
36. [Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis].
Michnar M; Milanowski J
Pneumonol Alergol Pol; 1996; 64 Suppl 1():90-6. PubMed ID: 9190245
[TBL] [Abstract][Full Text] [Related]
37. Ambroxol-induced modification of ion transport in human airway Calu-3 epithelia.
Hasegawa I; Niisato N; Iwasaki Y; Marunaka Y
Biochem Biophys Res Commun; 2006 May; 343(2):475-82. PubMed ID: 16546120
[TBL] [Abstract][Full Text] [Related]
38. Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive?
Scaglione F; Petrini O
Clin Med Insights Ear Nose Throat; 2019; 12():1179550618821930. PubMed ID: 30670922
[TBL] [Abstract][Full Text] [Related]
39. Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery.
Tewes F; Paluch KJ; Tajber L; Gulati K; Kalantri D; Ehrhardt C; Healy AM
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):604-13. PubMed ID: 23563102
[TBL] [Abstract][Full Text] [Related]
40. Mucoactive agents for airway mucus hypersecretory diseases.
Rogers DF
Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
